Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
4 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Climb Bio, Inc.’s names, not what it holds today.
Patents granted
4
4 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against none in 2024 and 2 in 2023
Applications published
9
since 2001, to Dec 31, 2025
Names they are printed under
4
a subsidiary, a former name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Eliem Therapeutics (UK) Ltd a subsidiary
named as the applicant on its applications, in GB
6 publishedELIEM THERAPEUTICS, INC. a former name
US, as the owner printed on each patent
1 publishedEliem Therapeutics, Inc. a former name
named as the applicant on its applications, in US
2 publishedEliem Therapeutics (UK) Ltd a subsidiary
GB, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Feb 7, 2023 | 11,571,432 | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof | Pharmaceuticals | Eliem Therapeutics (UK) Ltd |
| Jan 10, 2023 | 11,547,681 | N-acylethanolamide derivatives and uses thereof | Pharmaceuticals | ELIEM THERAPEUTICS, INC. |
| Aug 17, 2021 | 11,090,314 | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof | Pharmaceuticals | ELIEM THERAPEUTICS, INC. |
| Mar 2, 2021 | 10,933,037 | N-acylethanolamide derivatives and uses thereof | Pharmaceuticals | ELIEM THERAPEUTICS, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jul 18, 2024 | 2024/0238313 | DOSING OF CV-10155 IN THE EVENING OR PRIOR TO SLEEP TO TREAT GABAA DISORDERS | Pharmaceuticals | Eliem Therapeutics (UK) Ltd |
| Nov 23, 2023 | 2023/0372365 | METHODS OF TREATING FIBROMYALGIA WITH NEUROACTIVE STEROIDS | Pharmaceuticals | Eliem Therapeutics (UK) Ltd |
| Nov 23, 2023 | 2023/0372364 | METHOD OF TREATING GABA MEDIATED DISORDERS | Pharmaceuticals | Eliem Therapeutics (UK) Ltd |
| Jul 6, 2023 | 2023/0210870 | METHODS OF TREATING FEMALE HEALTH CONDITIONS RELATED TO SEX HORMONES | Pharmaceuticals | Eliem Therapeutics, Inc. |
| May 11, 2023 | 2023/0147799 | COMPOSITIONS THAT PREFERENTIALLY POTENTIATE SUBTYPES OF GABAA RECEPTORS AND METHODS OF USE THEREOF | Pharmaceuticals | Eliem Therapeutics (UK) Ltd |
| Sep 22, 2022 | 2022/0296614 | DOSING OF CV-10155 IN THE EVENING OR PRIOR TO SLEEP TO TREAT GABAA DISORDERS | Pharmaceuticals | Eliem Therapeutics (UK) Ltd |
| Sep 22, 2022 | 2022/0296613 | FOOD-INDEPENDENT DOSING OF CV-10155 TO TREAT GABAA DISORDERS | Pharmaceuticals | Eliem Therapeutics (UK) Ltd |
| Jul 8, 2021 | 2021/0205332 | COMPOSITIONS THAT PREFERENTIALLY POTENTIATE SUBTYPES OF GABAA RECEPTORS AND METHODS OF USE THEREOF | Pharmaceuticals | Eliem Therapeutics, Inc. · patent 11,571,432 granted from it |
| Apr 1, 2021 | 2021/0093589 | N-ACYLETHANOLAMIDE DERIVATIVES AND USES THEREOF | Pharmaceuticals | ELIEM THERAPEUTICS, INC. · patent 11,547,681 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.